What is it about?

AA amyloidosis is a rare disease characterized by the presence of renal involvement in almost all cases. Despite the typically good survival, progression to end-stage renal failure is frequent and affects quality of life. We identified and validated for the first time biomarker-based staging systems able to identify patients with more advanced disease at diagnosis.

Featured Image

Read the Original

This page is a summary of: Development and Validation of Staging Systems for AA Amyloidosis, Journal of the American Society of Nephrology, March 2024, Wolters Kluwer Health,
DOI: 10.1681/asn.0000000000000339.
You can read the full text:

Read

Contributors

The following have contributed to this page